Targeting translational read-through of premature termination mutations in BMPR2 with PTC124 for pulmonary arterial hypertension

Lu Long¹, Xudong Yang¹, Mark Southwood², Stephen Moore¹, Alexi Crosby¹, Paul D. Upton¹, Benjamin J. Dunmore¹ and Nicholas W. Morrell¹

¹Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK; ²Pathology Research, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK

Abstract
Pulmonary arterial hypertension is a fatal disorder of the lung circulation in which accumulation of vascular cells progressively obliterates the pulmonary arterioles. This results in sustained elevation in pulmonary artery pressure leading eventually to right heart failure. Approximately, 80% of familial and 20% of sporadic idiopathic pulmonary arterial hypertension cases are caused by mutations in the bone morphogenetic protein receptor type 2 (BMPR2). Nonsense mutations in BMPR2 are amongst the most common mutations found, where the insertion of a premature termination codon causes mRNA degradation via activation of the nonsense-mediated decay pathway leading to a state of haploinsufficiency. Ataluren (PTC124), a compound that permits ribosomal read-through of premature stop codons, has been previously reported to increase BMPR2 protein expression in cells derived from pulmonary arterial hypertension patients harbouring nonsense mutations. In this study, we characterised the effects of PTC124 on a range of nonsense BMPR2 mutations, focusing on the R584X mutation both in vitro and in vivo. Treatment with PTC124 partially restored BMPR2 protein expression in blood outgrowth endothelial cells isolated from a patient harbouring the R584X mutation. Furthermore, a downstream bone morphogenetic protein signalling target, Id1, was rescued by PTC124 treatment. Mutant cells also exhibited increased lipopolysaccharide-induced permeability, which was reversed by PTC124 treatment. Increased proliferation and apoptosis in R584X blood outgrowth endothelial cells were also significantly reduced by PTC124. Moreover, oral PTC124 increased lung BMPR2 protein expression in mice harbouring the R584X mutation (Bmpr2⁺/⁻/R584X). Our findings provide support for future experimental medicine studies of PTC124 in pulmonary arterial hypertension patients with specific nonsense BMPR2 mutations.

Keywords
pulmonary endothelium, mutations, translational research

Introduction
Pulmonary arterial hypertension (PAH) is a devastating disorder characterised by excessive fibroblasts, endothelial cells and smooth muscle cells in the lung vasculature. These aberrant cellular processes cause progressive occlusion of the pulmonary arterioles leading to a sustained elevation in pulmonary artery pressure and eventually right heart failure. Current therapies slow disease progression while also alleviating symptoms, but the only cure remains lung transplantation. Approximately 80% of families with PAH, and 20% of apparently idiopathic PAH cases, are due to autosomal dominant heterozygous germline

Corresponding author:
Nicholas W. Morrell, Division of Respiratory Medicine, Department of Medicine, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, United Kingdom.
Email: nwm23@cam.ac.uk
LL, XY, and BJD contributed equally to this work.
BJD and NWM are joint senior authors.

Creative Commons CC-BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
mutations in the bone morphogenetic protein receptor type 2 (BMPR2).\textsuperscript{1,4} BMP signalling regulates many processes related to growth, survival, differentiation and development. Upon BMP ligand stimulation, the constitutively phosphorylated BMPR2 heterodimerises with BMP type I receptors at the cell surface. A cascade of downstream signalling occurs through phosphorylation of proteins known as receptor-mediated Smads (R-Smads). R-Smads complex with the common partner Smad4, and translocate to the nucleus driving expression of target genes including the family of inhibitors of DNA-binding (Ids 1–4).\textsuperscript{5} We have previously shown that mutations in BMPR2 cause loss-of-function with a reduction in expression of many downstream signalling targets, and altered growth responses to BMP ligands.\textsuperscript{6–11}

Nonsense mutations introduce premature stop codons into the sequence of DNA. If the mRNA transcript is expressed and translated, this can result in a truncated, potentially non-functional protein. Alternately, the mutant transcript is unstable and is rapidly removed by nonsense-mediated mRNA decay (NMD),\textsuperscript{12} leading to complete absence of the mutant protein. It is estimated that 12% of known disease-causing mutations in the Human Gene Mutation Database are due to nonsense mutations,\textsuperscript{13} but the functional impact of the premature stop codon can be difficult to predict. Previous studies proposed that variants close to the 3’ end of a transcript might avoid NMD.\textsuperscript{14} However, a recent large-scale RNA-seq study suggested that up to 68% of variants predicted to cause NMD actually escape RNA surveillance.\textsuperscript{15} Since the discovery of mutations in BMPR2 predisposing individuals to PAH, over 300 distinct mutations have been identified with a significant proportion due to nonsense mutations (approximately 30%).\textsuperscript{3,16,17}

Aminoglycosides such as gentamicin have been used in proof-of-concept studies to suppress NMD as a way of treating cystic fibrosis (CF) and Duchenne muscular dystrophy (DMD).\textsuperscript{18–20} Indeed, gentamicin has been tested successfully in premature termination codon (PTC) BMPR2 mutations models.\textsuperscript{21,22} However, the risk of renal and otic toxicities due to the requirement of high doses have precluded the use of gentamicin as a therapeutic in this setting. Ataluren (also known as PTC124) is a small molecule non-aminoglycoside oxazolidone that promotes the read-through of premature stop codons. Using a high-throughput discovery screen, PTC124 was discovered and tested in vitro and in vivo as a potentially safer alternative to gentamicin.\textsuperscript{23,24} In clinical trials for both CF and DMD, PTC124 appeared safe and showed some promising efficacy.\textsuperscript{24–26} Given these promising findings, Drake et al. investigated the ability of PTC124 to improve BMP signalling and reverse the hyperproliferative phenotype in nonsense mutant BMPR2 endothelial cells.\textsuperscript{27}

In this study, we further characterised the potential therapeutic properties of PTC124 on a range of PTCs across the BMPR2 gene in patient-derived cells, and found major differences in the restoration of BMPR2 protein expression between BMPR2 mutations. Furthermore, we developed a mouse knock-in model for one of these mutations (R584X) to provide proof-of-concept that this approach might be useful in vivo for specific BMPR2 nonsense mutations.

**Materials and methods**

**Cell culture and treatments**

Human blood outgrowth endothelial cells (BOECs) were isolated from peripheral blood of PAH patients and healthy controls as previously described.\textsuperscript{28–30} All blood donors provided informed consent in accordance with the human study protocol – 07/H0306/134 (Cambridgeshire 3 Research Ethics Committee). Cells were cultured and expanded in Endothelial Cell Growth Medium-2 (EGM-2) (minus heparin) (Lanza, Slough, UK) with 10% Foetal Bovine Serum (FBS) (Thermo Fisher Scientific, Hemel Hempstead, UK). All experiments were performed with passage 5–7 cells. Human or mouse pulmonary artery smooth muscle cells (PASMCs) were isolated as previously described and cultured in DMEM (Invitrogen) containing 20% (v/v) FBS and A/A (DMEM/20% FBS).\textsuperscript{31} The Royal Papworth Hospital ethical review committee approved the use of the human tissues (Ethics Ref 08-H0304-56 + 5), and informed consent was obtained from all subjects. Recombinant human BMP9 was purchased from R&D Systems (Oxfordshire, UK). PTC124 was a kind gift from PTC Therapeutics (South Plainfield, NJ, USA) and was used at 100 μM overnight in all in vitro experiments.

**Immunoblotting**

Frozen lung tissue was homogenised in lysis buffer (250 mM Tris-HCl, pH 6.8, 4% SDS, 20% v/v glycerol and 1 x EDTA-free protease inhibitor cocktail – Roche, West Sussex, UK) and sonicated for approximately 1 min and then centrifuged for 15 min at 15,000 x g. BOECs were lysed in lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS and 1 x EDTA-free protease inhibitor cocktail). The protein concentration was determined using the Bio-Rad Lowry assay (Bio-Rad Laboratories, Hemel Hempstead, UK), using Bovine Serum Albumin (BSA) as the standard. Cell lysates (20–100 μg protein) were separated by SDS-PAGE and proteins were transferred to polyvinylidene fluoride membranes by semidry blotting (GE Healthcare, Buckinghamshire, UK). Membranes were then blocked and probed with a rabbit monoclonal antibody toward Id1 (clone 195-14, CalBioreagents, San Mateo, CA) or a mouse monoclonal antibody against BMPR2 (clone 181, BD Transduction Laboratories, Wokingham, Berkshire, UK). After washing, blots were incubated with secondary anti-mouse/rabbit horseradish peroxidase antibody (Dako, Cambridgeshire, UK) for 1 h at room temperature. As a
loading control, all blots were re-probed with a monoclonal antibody for either α-tubulin (clone DM1A, Sigma-Aldrich) or β-actin (clone AC-15, Sigma-Aldrich). Densitometry was performed using ImageJ software. Membranes were developed using enhanced chemiluminescence (GE Healthcare).

**Endothelial monolayer permeability**

Monolayer permeability was assessed as described previously. Briefly, transwell inserts (Corning, Corning, NY) were coated for 1 h at 37°C with 0.1 mg/ml bovine skin collagen (Sigma), washed twice with water and rinsed with medium before plating cells. BOECs (400,000 cells in 100 µl Complete EGM-2 medium) were plated in the top chamber and 700 µl of medium was added to the bottom chamber 24 h before addition of fresh medium to both chambers, with or without 5 ng/ml BMP9 or PTC124 (100 µM) in the upper chamber. After 30 min, 25 mM horseradish peroxidase (HRP) was added to the top chamber, with or without 0.4 µg/ml lipopolysaccharide (LPS) (Sigma). Medium (20 µl) was collected from the lower chamber every 15 min for 60 min. The HRP content of this medium was determined by measuring absorbance at 490 nm after the addition of 150 µl of o-phenylenediamine dihydrochloride buffer to each well of a 96-well plate.

**Cell proliferation**

For assessment of BOEC proliferation, cells were seeded at 40,000 cells/well in 24-well plates and left to adhere overnight. After 24 h, cells were then exposed to the stated treatments in EBM-2 containing 2% FBS and A/A. Treatments were replenished every 48 h. For assessment of mouse PASMC proliferation, cells were seeded at 30,000 cells/well in 24-well plates and left to adhere overnight. After 24 h, cells were then exposed with or without PTC124 100 µM in complete culture media for 48 h. At the relevant time points, cells were trypsinised and counted on a haemocytometer using trypan blue exclusion to assess cell viability.

**Apoptosis**

Prior to addition of an apoptotic stimulus, BOECs were seeded into EBM-2 basal media (Lonza) with 2% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin and 0.25 mg/ml amphotericin B, but without any growth factor supplements for 16 h. During this incubation, cells were maintained with or without PTC124 (100 µM) for the indicated period. Following the 16 h incubation, cells were either left unstimulated or treated for 6 h with 10 ng/ml Tumour Necrosis Factor-a (TNFα) and 20 µg/ml cycloheximide to induce apoptosis. Following the apoptotic stimulus, cells were trypsinised and stained with FITC-conjugated annexin V and propidium iodide (PI, BD Biosciences, Wokingham, UK) as per the manufacturer’s instructions and assessed by flow cytometry. Apoptotic cells were defined as positive for Annexin-V staining and negative for PI staining.

**RNA preparation and quantitative reverse transcriptase polymerase chain reaction**

Total RNA was extracted using the RNeasy Mini Kit with DNase digestion (Qiagen, West Sussex, UK). cDNA was prepared from ~1 µg of RNA using the High Capacity Reverse Transcriptase kit (Applied Biosystems, California, USA), according to the manufacturer’s instructions. All qPCR reactions were prepared in MicroAmp® optical 384-well reaction plates (Applied Biosystems) using 50 ng/µl cDNA with SYBR®Green Jumpstart® Taq Readymix™ (Sigma-Aldrich), ROX reference dye (Invitrogen) and sense and anti-sense primers (all 200 nM). Primers for human: BMPR2, ACTB; mouse: Bmpr2, Actb, B2m and Hprt were all designed using Primer3 (http://primer3.sourceforge.net/). Reactions were amplified on a QuantStudio 6Flex Real-Time PCR system (Applied Biosystems). In human BOECs, target gene expression was normalised to ACTB and the difference in the amount of product produced was expressed as a fold change. Relative expression of each target gene was identified using the comparative 2-ΔΔCt method. In mouse lung, target gene expression was normalised to Actb, B2m and Hprt and the difference expression represented as relative expression.

**Puromycin incubation and RNA isolation**

The following protocol was adapted from Hamid and colleagues. BOECs or PASMCs were cultured in full growth media in 6 cm dishes until confluence and then incubated with or without puromycin (100 µg/ml, Sigma Aldrich) 16 h prior to harvesting. RNA was harvested using the RNeasy Mini kit (Qiagen) following the manufacturer’s instructions.

**Reverse transcriptase polymerase chain reaction of BMPR2**

Total RNA (~3 µg) was used as a template for cDNA synthesis. Following the manufacturer’s protocol, first-strand cDNA synthesis was performed using SuperScript™ First-Strand System (Thermo Fisher Scientific) with an oligo-dT primer. A tenth of the first-strand reaction volume was then used as a template for PCR amplification. Reverse transcriptase polymerase chain reaction (RT-PCR) primers were as follows: W9X – CTTTGCCCTCCTGTATCTTGG (forward) and CTGCATGCTCCATAGGT (reverse); R213X – GAAATGATGAGGCAGCAG (forward) and CTCCATGAAATGGCAGGT (reverse); R321X – AAGTCGATGGCAGG (reverse) and CCGCGACGTCTATTTTGG (forward); and CGTGAGTCCTGTGGTGTTTG (reverse); R899X –
CAACAAGCTGGCCATGATGA (forward) and TGCAAGGTAACACGAGTGTC (reverse). RT-PCR amplification was conducted using the Elongase™ Enzyme Mix (Thermo Fisher Scientific). Cycling parameters were as follows: initialisation step – 30 s at 94°C; amplification step (55 cycles) – 94°C for 30 s, 58°C for 30 s, 68°C for 3 min 30 s; extension step – 68°C for 5 min. cDNA products were visualised by agarose gel electrophoresis.

DNA sequencing of RT-PCR products

Prior to sequencing, BMPR2 RT-PCR products were purified with ExoSAP-IT™ PCR Product Cleanup reagent (Thermo Fisher Scientific) according to the manufacturer's protocol. Sequencing reactions were performed using the BigDye™ Terminator v3.1 Cycle Sequencing kit (Thermo Fisher Scientific) according to the manufacturer's protocol. Samples were then sequenced.

Bmpr2⁺/R584X knock-in mouse model

For all animal work, group sizes were determined using estimates of variance and minimum detectable differences between the groups that were based on our past experience with rodent models of PAH. Animals were randomised using an assigned animal identification number, allowing investigators performing all cardiopulmonary phenotyping and histological analyses to be blinded to animal genotype and treatment group. All animal work was carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and approved under Home Office Project License 80/2460.

The Bmpr2⁺/R584X knock-in mouse model was generated by GenOway (Lyon, France). Supplementary Fig. 5 depicts an overview of the strategy used to generate the R584X mutant. A targeting vector containing the R584X mutation in exon 12 was generated. Upstream of the 3’ short homology arm a lox-P flanked neomycin cassette was inserted. PCR screening and Southern blot screening were conducted to detect homologous recombination after electroporation into embryonic stem (ES) cells. Sequence analysis was then conducted to ascertain presence of the R584X mutation. Recombined ES cell clones were injected into blastocysts. To generate chimeric male carrying the recombined locus, blastocysts were implanted in pseudo-pregnant females and allowed to develop to term. Chimerism was assessed based on coat colour. Chimeric males were then mated with Cre-deleter mice to excise the loxP-flanked neomycin cassette. Progeny was assessed by genotype analysis.

PTC124 treatment of Bmpr2⁺/R584X animals

Littermate controls (Bmpr2⁺/+; n = 12) and R584X knock-in (Bmpr2⁺/+; n = 12) mice were randomised into two groups. One group was fed chow supplemented with PTC124 (0.3% PTC124) supplied by PTC Therapeutics (South Plainfield, NJ, USA) for two weeks. The other group was fed a standard chow diet for two weeks. Mice were anesthetised with isoflurane inhalation and then either assessed haemodynamically or mice were exsanguinated and the lungs were removed for further analysis. Lungs were either fixed in situ in the distended state by infusion of 10% buffered formalin into the pulmonary artery (at 25 mmHg pressure) via the trachea and overnight fixation in 4% formalin prior to embedding in paraffin, or immediately frozen in liquid nitrogen for protein or RNA isolation.

Where indicated in the relevant results section, catheterisation of the right ventricle (RV) was undertaken via cannulation of the right internal jugular vein using a Millar SPR-139 catheter (Millar Instruments, Houston, TX) connected to PowerLab hardware utilising LabChart 8 (ADInstruments, Oxford, UK). Mice were then sacrificed and the hearts and lungs were harvested. Right ventricular hypertrophy (RVH) was assessed by removing the heart and dissecting the RV free wall from the left ventricle plus septum (LV+S) and weighing separately. The degree of RVH was determined from the ratio RV/LV + S.

Assessment of pulmonary vascular remodelling

In order to assess pulmonary arteriolar muscularisation, sections of fixed mouse lung tissue (5 μm in thickness) were labelled with monoclonal mouse-anti-smooth muscle α-actin (SMA) (clone 1A4, Dako, Glostrup, Denmark), followed by polyclonal goat anti-mouse HRP. To detect staining, the Dako ARK™ kit (Dako) was used in accordance with the manufacturer’s instructions. Antibody staining was visualised using 3-3’ dianinobenzidine hydrochloride as substrate-chromogen and counterstained with Carrazzi haematoxylin. Pulmonary arteriolar muscularisation was assessed by the identification of alveolar ducts and categorisation of the accompanying intra-acinar artery as non-, partially or fully muscularised. Assessment of muscularisation was performed in a blinded fashion by a single researcher, to reduce operator variability, who was not aware of the group allocation of the samples being analysed.

PTC124 measurement in serum

PTC124 concentration in mouse serum was conducted using Liquid Chromatography with Mass Spectrometry (LC/MS/MS). Serum was isolated from blood samples collected in EDTA tubes at days 7 and 14 by tail vein bleed. Blood samples were centrifuged at 2000 x g for 5 min, and the serum fraction was extracted and stored at −80°C. Samples were analysed using LC/MS/MS by PTC Therapeutics using a UPLC I-Class System and Xevo TQ-S Spectrometer (Waters Corporation, Milford, MA, USA). Briefly, a standard curve of PTC124 was generated (0.01–5 μg/ml). Samples were diluted with 16% methanol and...
1 μg/ml D4-124 in acetonitrile. Samples were placed on an automatic shaker for 5 min before centrifugation at 2000 r/min for 2 min prior to injecting onto the LC/MS/MS system.

**Statistics**

All data were analysed using GraphPad Prism. Data are presented as mean±SEM. Data were analysed by one-way/two-way ANOVA with post-hoc Tukey’s honestly significant difference (HSD) analysis or paired two-tailed Student’s t-test where indicated. *P* < 0.05 was considered significant.

**Results**

**Reduced BMPR2 protein expression in BOECs from patients harbouring nonsense BMPR2 mutations versus controls**

BOECs were available from four patients with nonsense mutations in *BMPR2* (W9X, R213X, R321X and R584X), and one patient with a missense mutation in the kinase domain of *BMPR2* (C347R). A further PASMC line was available from a PAH patient with a nonsense *BMPR2* mutation (R899X) (Supplementary Fig. 1 and Table 1). BMPR2 protein expression was assessed in BOECs from control subjects and *BMPR2* mutant PAH patients. In all mutation patients, BMPR2 protein expression was significantly reduced when compared to BOECs isolated from controls (Fig. 1a and b). In addition, *BMPR2* mRNA expression in nonsense *BMPR2* mutations was significantly reduced (Fig. 1c).

**NMD contributes to reduced expression of mutant transcripts**

The reduced mRNA and protein expression and the absence of truncated BMPR2 protein species is consistent with the mutations giving rise to an unstable mRNA transcript that is susceptible to NMD, leading to a state of haploinsufficiency. To assess the abundance of wild-type and mutant mRNA species, heterozygous mutant BOECs from PAH patients were used. The relative abundance of wild-type and mutant transcripts was assessed by sequencing of cDNA following RT-PCR. In general, all nonsense mutations gave rise to a greatly reduced level of mutant transcript, as evidenced by very low chromatogram signals (Fig. 1d and e; Supplementary Fig. 2a and c). The level of mutant transcript varied between mutations with R584X showing the highest transcript level and W9X the lowest. To demonstrate whether NMD was contributing to the reduced mutant transcript level, BOECs were treated with puromycin to suppress NMD. Treatment with puromycin increased transcripts of the mutant alleles for all mutations (Fig. 1d and e; Supplementary Fig. 2a) except W9X (Supplementary Fig. 2c). We also assessed the effect of puromycin treatment in PASMCs harbouring a R899X mutation. The baseline R899X transcript level was also greatly reduced, but increased following treatment with puromycin (Supplementary Fig. 2b). In Table 2, the predominant transcript is highlighted in bold and the relative fold-change of the mutant transcript versus the wild-type is detailed, ± puromycin treatment.

**PTC124 treatment improves BMPR2 protein expression and downstream signalling in R584X cells**

BOECs harbouring heterozygous R213X, R321X and R584X mutations were treated with PTC124 (100 μM) for 24 h. BMPR2 protein expression was significantly increased by PTC124 in R584X mutant cells but not in R213X or R321X cells (Fig. 2a and b). It is worth noting that PTC124 had no effect upon BMPR2 protein expression in control BOECs (Supplementary Fig. 3). Furthermore, PTC124 consistently increased Id1 protein levels as a marker of BMPR2 signalling in R584X mutant BOECs (Fig 2c and d). No effect on Id1 levels was observed in control BOECs (Supplementary Fig. 3).

**Endothelial dysfunction in the R584X mutant is restored by PTC124 treatment**

We next questioned whether PTC124 could restore the functional impact of *BMPR2* mutation on endothelial cells. First, we examined the effect of PTC124 on endothelial barrier integrity. Monolayer integrity was determined by measuring the amount of horseradish peroxidase leak into the bottom chamber in transwell experiments. Consistent with the results of our previous studies, BMP9 treatment inhibited LPS-induced monolayer permeability in both wild-type and *BMPR2* mutant cells (Fig. 3a and b; Supplementary Fig. 4a and b). Furthermore, the *BMPR2* mutant BOECs demonstrated greater permeability in the presence of LPS compared to wild-type cells (Fig. 4a and b; Supplementary Fig. 4a and b). Treatment with PTC124 had no effect on monolayer integrity after LPS stimulation in wild-type or R321X BOECs (Fig. 3a; Supplementary Fig. 4a and b). However, in R584X BOECs, PTC124 alone significantly reduced the LPS-induced permeability (Fig. 3b).

Since increased endothelial apoptosis is considered a critical response to injury in *BMPR2* mutant endothelial cells, we next examined the effect of PTC124 treatment on apoptosis. As previously reported, we observed that BOECs harbouring *BMPR2* mutants demonstrate an increased susceptibility to TNFα-induced apoptosis (Fig. 4a; Supplementary Fig. 5a). Only BOECs with the R584X mutation showed reduced apoptosis when treated with PTC124 (Fig. 4a). TNFα-induced apoptosis in BOECs harbouring the R321X mutation was unaffected by treatment with PTC124 (Supplementary Fig. 5a).

Finally, we assessed the hyperproliferation of mutant BOECs and the effect of PTC124 treatment. Our group
Puromycin treatment increases BMPR2 R584X mutant transcript. (a) Protein lysates were extracted from blood outgrowth endothelial cells (BOECs) from wild-type ($n = 3$) and BMPR2 mutant ($n = 5$) patients. Lysates were immunoblotted for BMPR2 and loading control, $\alpha$-tubulin. (b) Densitometry analysis of the ratio between BMPR2 and $\alpha$-tubulin. (c) BMPR2 mRNA expression of BOECs harbouring nonsense mutations was assessed and normalised to ACTB. (d and e) BOECs harbouring a R584X or R321X were treated overnight with puromycin (100 mg/ml). Following RNA isolation, amplified RT-PCR products were sequenced. Chromatograms for R584X (d) and R321X (e) show the effects of puromycin treatment on transcript expression. One-way ANOVA. *$P \leq 0.05$. Error bars represent mean ± SEM.

BMPR2: bone morphogenetic protein receptor type 2.
has previously shown that BOECs with BMPR2 deficiency are hyperproliferative. Both BOECs harbouring the R321X and R584X mutations exhibited hyperproliferation when compared to wild-type BOECs (Fig. 4b; Supplementary Fig. 5b). Again, only the R584X mutation was significantly affected by PTC124 treatment with a similar reduction in hyperproliferation compared to BMP9 treatment (Fig. 4b). Only BMP9 treatment significantly reduced hyperproliferation in R321X mutant cells (Supplementary Fig. 5b).

**PTC124 improves BMPR2 protein expression in a R584X mouse model**

Given that PTC124 exerted promising effects on endothelial function and BMPR2 protein expression in vitro, we developed a knock-in mouse harbouring a heterozygous R584X mutation (Bmpr2<sup>þ/R584X</sup>) (Supplementary Fig. 6) to test the effects of PTC124 in vivo. Similar to the findings in patient-derived BOECs, BMPR2 protein and mRNA was significantly reduced in the Bmpr2<sup>þ/R584X</sup> mouse lungs compared to littermate controls (Fig. 5a, b and e). Mutant Bmpr2<sup>þ/R584X</sup> and littermate controls were fed either standard chow or chow supplemented with 0.3% PTC124 over a two-week period. Treatment with PTC124 significantly increased BMPR2 protein expression in Bmpr2<sup>þ/R584X</sup> mouse lungs (Fig. 5a and d), with no effect observed in wild-type animals (Fig. 5a and c). Furthermore, mRNA levels in either wild-type or R584X mutant animals in the presence of PTC124 remained unaffected (Fig. 5f and g).

**Discussion**

Nonsense mutations account for approximately 30% of BMPR2 mutations underlying heritable PAH. We have previously proposed that correcting premature stop codons introduced by these mutations might be an approach to treat patients with PAH who carry these mutations. Ataluren (PTC124) has been used in clinical trials in the treatment of CF and DMD promoting translational readthrough of truncating mutations in CF transmembrane conductance regulator (CFTR) and dystrophin, respectively. Our findings suggest that nonsense mutations in

---

**Table 1. Demographics of BMPR2 mutant BOECs.**

| Gender | Age | Ethnicity | mPAP |
|--------|-----|-----------|------|
| W9X    | Female | 35 | Caucasian | 65 |
| R213X  | Female | 36 | Asian | 40 |
| R321X  | Male | 45 | Caucasian | 46 |
| R584X  | Female | 79 | Caucasian | 52 |
| R899X  | Female | 30 | N/A | N/A |
| C347R  | Male | 27 | Caucasian | N/A |

**Table 2. Puromycin treatment of BMPR2 mutant BOECs.**

| Wild-type allele | Mutant allele | Puromycin negative | Ratio of M/W (fold change) | Puromycin positive | Ratio of M/W (fold change) |
|------------------|---------------|---------------------|---------------------------|-------------------|--------------------------|
| W9X              | TGG           | TGA                 | 0.079                     | TGG               | 0.106                    |
| R213X            | CGA           | TGA                 | 0.154                     | CGA               | 0.609                    |
| R321X            | CGA           | TGA                 | 0.153                     | CGA               | 0.568                    |
| R584X            | CGA           | TGA                 | 0.587                     | TGA               | 1.697                    |
| R899X            | CGA           | TGA                 | 0.259                     | CGA               | 0.545                    |

Note: The fold change is calculated by the ratio of the mutant allele peak height/wild-type peak height in the appropriate chromatograms.
Fig. 2. PTC124 treatment increases BMPR2 protein expression and downstream signalling in R584X mutant BOECs. (a) BOECs isolated from patients harbouring R213X, R321X and R584X were treated with either PTC124 (100 μM) for 24 h. Lysates were immunoblotted for BMPR2 and loading control, α-tubulin (n = 3). (b) Densitometry analysis of the ratio between BMPR2 and α-tubulin. (c) R584X mutant BOECs were treated with PTC124 (100 μM) for 24 h. Representative immunoblot for Id1 and loading control, α-tubulin (n = 3). (d) Densitometry analysis of the ratio of α-tubulin compared to Id1 (n = 3). Student’s t-test. *P ≤ 0.05. Error bars represent mean ± SEM.

BMPR2: bone morphogenetic protein receptor type 2.
that lead to the introduction of a PTC trigger robust NMD and do not lead to the expression of a truncated BMPR2 protein. In fact, the impact of NMD is such that the mutant BMPR2 transcripts are generally expressed at a very low level. This is of major importance for therapeutic approaches, such as PTC124, that act by enhancing translational read-through of the mRNA. In the absence of BMPR2 mRNA, these drugs lack the substrate to initiate ribosomal translation into protein. Nevertheless, we identified at least one BMPR2 mutation, R584X, that demonstrated measurable levels of mRNA. In this specific case, we were able to show that PTC124 increased the expression of BMPR2 protein and downstream signalling both in vitro and in vivo.

We have previously established a number of functional assays such as vascular permeability, apoptosis and proliferation to test the effectiveness of BMP9 treatment on endothelial cell function. Using these methods, we assessed the ability of PTC124 to rescue the R584X mutant BOECs. We compared cells harbouring the R584X mutation with BOECs expressing R321X, a BMPR2 mutation that previously showed little or no increase in BMPR2 protein expression following PTC124 treatment. Both cell

![Fig. 3. PTC124 treatment promotes monolayer integrity in R584X mutant BOECs. Permeability was assessed in monolayers of wild-type (a) (n = 3) and R584X mutant (b) (n = 3) BOECs treated with either PTC124 (100 μM) or BMP9 (5 ng/ml) and/or LPS (400 ng/ml). Colorimetric absorbance of HRP was measured after incubation periods every 15 min until 1 h. One-way ANOVA. *P < 0.05. Error bars represent mean ± SEM. LPS: lipopolysaccharide; PTC: premature termination codon.](image)

![Fig. 4. PTC124 treatment prevents apoptosis and hyperproliferation in R584X mutant BOECs. (a) Quantification of apoptotic (Annexin-V+/PI-) wild-type (n = 3) and R584X mutant BOECs (n = 3) after PTC124 treatment for 24 h prior to the addition of TNFα (10 ng/ml) and cycloheximide (20 microgram/ml) for six hours. (b) Proliferation assessment of wild-type (n = 3) and R584X mutant (n = 3) BOECs after day 6, following PTC124 (100 μM) or BMP9 (5 ng/ml) treatment. One-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Error bars represent mean ± SEM. PTC: premature termination codon; BMP: bone morphogenetic protein.](image)
Fig. 5. PTC124 treatment rescues low BMPR2 protein expression. Littermate controls (Bmpr2+/+) and R584X knock-in (Bmpr2+/R584X) mice were randomised into two treatment groups. One group was fed chow supplemented with PTC124 and the other group were fed a standard chow diet for two weeks. (a) Lungs were isolated from wild-type (Bmpr2+/+) (n = 3); wild-type plus PTC124 (Bmpr2+/+ + PTC124) (n = 3); R584X knock-in (Bmpr2+/R584X) (n = 3); R584X knock-in (Bmpr2+/R584X + PTC124) (n = 3). Protein lysates were extracted and immunoblotted for BMPR2 and loading control, α-tubulin (n = 3). (b) Densitometry analysis of the ratio between BMPR2 and α-tubulin in Bmpr2+/+ versus Bmpr2+/R584X. (c) Densitometry analysis of the ratio between BMPR2 and α-tubulin in Bmpr2+/+ versus Bmpr2+/+ + PTC124. (d) Densitometry analysis of the ratio between BMPR2 and α-tubulin in Bmpr2+/R584X versus Bmpr2+/R584X + PTC124. (e to g) Lungs were isolated from wild-type (Bmpr2+/+) (n = 7); wild-type plus PTC124 (Bmpr2+/+ + PTC124) (n = 4); R584X knock-in (Bmpr2+/R584X) (n = 7); R584X knock-in (Bmpr2+/R584X + PTC124) (n = 3). Bmpr2 mRNA expression was assessed and normalised to three endogenous controls (Actb, B2m and Hprt). (h) PTC124 levels was measured by MS/LC/LC in the serum of PTC124 treated animals at day 7 and day 14. Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001. Error bars represent mean ± SEM.

PTC: premature termination codon; BMPR2: bone morphogenetic protein receptor type 2.
lines exhibited increased vascular permeability compared to the wild-type controls in the presence of LPS which was abrogated by BMP9 treatment. Only cells expressing R584X mutation responded to PTC124 treatment. Of note, no differences were observed with combined BMP9 and PTC124 treatment. Furthermore, the significant increase in apoptosis in both mutant cell lines was only normalised by PTC124 in the R584X BOECs. Similarly, the hyperproliferation phenotype of both BMPR2 mutants was only corrected by PTC124 in the R584X mutant line. Interestingly, BMP9 attenuated the increased proliferation in both BMPR2 mutant cells.

Given these findings, a knock-in R584X mouse model was established. Unfortunately, a lack of haemodynamic or vascular remodelling phenotype was observed in the model. Our experience with other genetic mouse models such as the C118W knock-in mouse, the R899X knock-in, or Bmpr2 heterozygous null mouse is that these animals develop mild or no pulmonary hypertension, sometimes age-related, but do exhibit morphological evidence of pulmonary vascular remodelling. Therefore, the lack of a pulmonary hypertension phenotype in the Bmpr2R584X mouse model is not unexpected. It was more surprising that the mouse exhibited no evidence of pulmonary vascular remodelling. One explanation is that the deficiency of Bmpr2 in this mouse is less profound than in other Bmpr2 deficient models. This is supported by the appearance of homozygous Bmpr2R584X/R584X mice in our breeding colony. Nevertheless, the Bmpr2+/R584X mouse proved a useful model to demonstrate proof-of-concept and target engagement in the presence of PTC124. Correction of molecular phenotypes was observed in these animals in the presence of PTC124. First, PTC124 was administered in the diet and serum levels indicated therapeutic levels of the drug at weeks 1 and 2 post administration in both wild-type and Bmpr2+/R584X mice. Similar to our in vitro observations in human BOECs, Bmpr2 protein and mRNA expression was significantly reduced in the mutant animals. Treatment with the PTC124 significantly enhanced Bmpr2 protein expression. Furthermore, PTC124 reduced the hyperproliferation of PASMCs isolated from the R584X mutant mouse model.

It appears that PTC124 may have a limited therapeutic role for PAH patients harbouring nonsense mutations in BMPR2. The reasons for this could include the efficiency of NMD triggered by these different mutations. The disease-causing PTC mutations we investigated were localised to four domains of the BMPR2 protein – extracellular, transmembrane, kinase and cytoplasmic tail domain. However, the impact and efficiency of NMD are hard to predict. The most commonly proposed mechanism of NMD is the canonical exon junction complex (EJC) model. Ordinarily, EJC proteins bind at exon–exon junctions until they are stripped from mRNAs by the translating ribosome following nuclear export. However, if a PTC is present 50 nucleotides upstream of the last exon boundary, then the EJC remains bound triggering NMD. A proposed exception to this model occurs when PTC transcripts in close proximity to the start codon circumvent NMD by reinitiating translation. Lindeboom and colleagues used matched exome and transcriptome data from over 9000 human tumours to further understand the principles governing NMD. First, in the human tumour data, the NMD efficiency correlated with the proximity of the PTC to the start codon and the last exon. Second, significant reduction in NMD was observed in PTCs that were found in the extremely long exons. Furthermore, the distance between PTC and the downstream exon junction leads to lower degradation rates. Applying the rules to the PTC mutations we tested in BMPR2 may go some way to deciphering why R584X is more susceptible to treatment with PTC124. All mutations tested were 50 nucleotides upstream of the last exon boundary. Only R584X and R899X are located in an exceptionally long exon (exon 12), and the R584X mutation is furthest away from the normal translational stop codon. Therefore, this could make the R584X mutation more likely to be less efficient at NMD.

DMD is caused by mutations in the dystrophin protein. More than 7000 mutations are associated with either DMD or Becker muscular dystrophy. As the largest human gene, DMD is susceptible to a high mutation rate, which underlies the large variation of mutations detected in the gene. The majority of DMD patients have deletions or duplications in.

**Fig. 6.** Bmpr2+/R584X PASMCs hyperproliferation is rescued by PTC124 treatment. Mouse PASMCs were isolated from lungs of wild-type or R584X mutant animals. Proliferation assessment of Bmpr2+/+ (n = 3) and Bmpr2+/R584X (n = 3) PASMCs after day 6, following PTC124 (100 µM) treatment. One-way ANOVA. *P ≤ 0.05. Error bars represent mean ± SEM.

PTC: premature termination codon; BMPR2: bone morphogenetic protein receptor type 2.
one or more exons, but a small proportion of patients are due to small insertions or deletions (~20%) with a number due to nonsense mutations inserting a premature stop codon with approximately ~10% of dystrophinopathies due to nonsense mutations. In a phase 2b controlled trial, PTC124 was shown to slow disease progression, in boys ≥5 years with a nonsense mutation dystrophinopathy, using the six-minute walk distance (6MWD) as the primary endpoint. However, in a subsequent phase 3 randomised, double-blinded trial with PTC124, there was no significant difference between the placebo and treated groups based on 6MWD. However, the authors of this study proposed that clinical significance was reached in a subgroup of patients. The authors concluded that ongoing trials should be conducted to assess the long-term benefits and safety of PTC124.

The efficacy of PTC124 has been assessed in CF. In approximately 5–10% of CF patients, nonsense mutations in the gene encoding the CFTR are causative of disease and exhibit a severe clinical phenotype. A preclinical investigation suggested that PTC124 improved the generation of functional CFTR in an animal model of CF due to a nonsense mutation (G542X). Also, a short-term proof-of-concept trial in patients with nonsense mutations improved epithelial electrophysiological abnormalities caused by dysfunctional CFTR. An extended 12-week study with PTC124 in 19 patients with at least one CFTR nonsense mutation improved total chloride transport. Furthermore, improved CFTR function was associated with improved pulmonary function and reduced CF-related coughing. However, in 2017, PTC therapeutics abandoned a 48-week phase 3 clinical trial as the two primary endpoints were un-met.

Overall, the clinical trials for both CF and DMD provided inconclusive evidence for the effectiveness of PTC124 as a therapy. However, every study reported that the drug was well tolerated with few toxic side effects. As discussed above, the rules governing NMD are complex and efficiency depends on the location of the PTC in the gene. As we have shown in this study, it is possible that PTC124 could provide benefit to a specific subset of PAH patients where NMD is less efficient. For example, apart from R584X, there are seven nonsense mutations (Y543X, R597X, Q657X, E661X, E672X, Y708X and Q720X) in exon 12 of BMPR2 that might be benefited by drugs that enhance translational read-through. The availability of BOECs derived from patients provides an opportunity to test in vitro whether individual BMPR2 mutations might benefit from PTC124. This approach could be used as a biomarker in experimental medicine studies and to select patients for inclusion in clinical trials.

Conflict of interest
The author(s) declare that there is no conflict of interest.

Funding
B.J.D., L.L., X.D.Y., S.M., A.C., P.D.U. were funded by the British Heart Foundation. This work was funded by awards to N.W.M. (British Heart Foundation Program Grant (RG/13/4/30107) and British Heart Foundation Special Project Grant (SP/12/12/29836)). Infrastructure support was provided by the Cambridge National Institute for Health Research Biomedical Research Center.

Supplemental material
Supplemental material for this article is available online.

References
1. International PPHC, Lane KB, Machado RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81–84.
2. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737–744.
3. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S32–S42.
4. Evans JD, Girend B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med 2016; 4: 129–137.
5. Massague J, Seoane J and Wotton D. Smad transcription factors. Genes Dev 2005; 19: 2783–2810.
6. Jeffery TK, Upton PD, Yang X, et al. Does BMPR2 mutation disrupt pulmonary vasculogenesis?. Chest 2005; 128: 602S.
7. Sobolewski A, Rudarakanchana N, Upton PD, et al. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. Hum Mol Genet 2008; 17: 3180–3190.
8. Affara M, Sanders D, Araki H, et al. Vasohibin-1 is identified as a master-regulator of endothelial cell apoptosis using gene network analysis. BMC Genomics 2013; 14: 23.
9. Caruso P, Dunmore BJ, Schlomser K, et al. Identification of microRNA-124 as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension via PTBP1 (polypyrimidine tract binding protein) and pyruvate kinase M2. Circulation 2017; 136: 2451–2467.
10. Long L, Yang X, Southwood M, et al. Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. Circ Res 2013; 112: 1159–1170.
11. Long L, Orniston ML, Yang X, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 2015; 21: 777–785.
12. Isken O and Maquat LE. Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function. Genes Dev 2007; 21: 1833–1856.
13. Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 2014; 133: 1–9.
14. Nagy E and Maquat LE. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem Sci 1998; 23: 198–199.
15. Lappalainen T, Sammeth M, Friedlander MR, et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 2013; 501: 506–511.

16. Graf S, Haimel M, Bleda M, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun 2018; 9: 1416.

17. Machado RD, Southgate L, Eichstaedt CA, et al. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. Hum Mutat 2015; 36: 1113–1127.

18. Politano L, Nigro G, Nigro V, et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003; 22: 15–21.

19. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163: 1683–1692.

20. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433–1441.

21. Nasim MT, Ghouri A, Patel B, et al. Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension. Hum Mol Genet 2008; 17: 1683–1694.

22. Hamid R, Hedges LK, Austin E, et al. Transcripts from a novel BMPR2 termination mutation escape nonsense mediated decay by downstream translation re-initiation: implications for treating pulmonary hypertension. Clin Genet 2010; 77: 280–286.

23. Austin ED, Phillips JA, Cogan JD, et al. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res 2009; 10: 87.

24. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87–91.

25. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719–727.

26. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Mol Genet Hum Genet 1998; 18: 5272–5283.

27. Denham R, Groom L, Gruenberg S, et al. Effect of ataluren supplementation on pulmonary function in cystic fibrosis. Thorax 2006; 61: 337–342.

28. Geti I, Ormiston ML, Rouhani F, et al. A practical and efficient cellular substrate for the generation of induced pluripotent stem cells from adults: blood-derived endothelial progenitor cells. Stem Cells Transl Med 2012; 1: 855–865.

29. Ormiston ML, Deng Y, Stewart DJ, et al. Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension. Am J Respir Cell Mol Biol 2010; 43: 546–554.

30. Ormiston ML, Toshner MR, Kiskin FN, et al. Generation and culture of blood outgrowth endothelial cells from human peripheral blood. J Vis Exp 2015; e53384. DOI: 10.3791/53384.

31. Yang X, Long L, Southwood M, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005; 96: 1053–1063.

32. Harrington EO, Brunelle JL, Shannon CJ, et al. Role of protein kinase C isoforms in rat epithidymal microvascular endothelial barrier function. Am J Respir Cell Mol Biol 2003; 28: 626–636.

33. Beppu H, Kawabata M, Hamamoto T, et al. BMP type II receptor is required for gasrulation and early development of mouse embryos. Dev Biol 2000; 221: 249–258.

34. Dunmore BJ, Yang X, Crosby A, et al. 4PBA Restores signaling of a cysteine-substituted mutant BMPR2 receptor found in patients with PAH. Am J Respir Cell Mol Biol. Epub ahead of print 2020. DOI: 10.1165/rcmb.2019-0321OC.

35. Davies RJ, Holmes AM, Deighton J, et al. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-beta in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Am J Physiol Lung Cell Mol Physiol 2012; 302: L604–L615.

36. Long L, MacLean MR, Jeffery TK, et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006; 98: 818–827.

37. Zhang J, Sun X, Qian Y, et al. At least one intron is required for the nonsense-mediated decay of triosephosphate isomerase mRNA: a possible link between nuclear splicing and cytoplasmic translation. Mol Cell Biol 1998; 18: 5272–5283.

38. Tummaru R, Neu-Yilik G, Deters A, et al. Binary specification of nonsense codons by splicing and cytoplasmic translation. EMBO J 1998; 17: 3484–3494.

39. Zhang Z, Lee CH, Mandiyan V, et al. Sequence-specific recognition of the internalization motif of the Alzheimer’s amyloid precursor protein by the X11 PTB domain. EMBO J 1997; 16: 6141–6150.

40. Romao L, Inacio A, Santos S, et al. Nonsense mutations in the human beta-globin gene lead to unexpected levels of cytoplasmic mRNA accumulation. Blood 2000; 96: 2895–2901.

41. Lindeboom RG, Supek F and Lehner B. The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet 2016; 48: 1112–1118.

42. Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 2015; 36: 395–402.

43. Dent KM, Dunn DM, Von Niederhausern AC, et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 2005; 134: 295–298.

44. Bashki K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014; 50: 477–487.

45. McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390: 1489–1498.

46. Bobadilla JL, Macek M Jr, Fine JP, et al. Cystic fibrosis: a current perspective on long-term outcome data and application to screening. Am J Respir Crit Care Med 2001; 163: 575–606.

47. De Gracia J, Mata F, Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax 2005; 60: 558–563.

48. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human muscular dystrophy mutations. Nature 2008; 447: 3484–3494.
CFTR-G542X nonsense allele in a CF mouse model. *Proc Natl Acad Sci U S A* 2008; 105: 2064–2069.

49. Konstan MW, VanDevanter DR, Rowe SM, et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). *J Cyst Fibros*. Epub ahead of print 2020. DOI: 10.1016/j.jcf.2020.01.007.

50. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. *Hum Mutat* 2006; 27: 121–132.